A search was conducted in MEDLINE, Scopus, Web of Science, and Embase databases until March 30th, 2023. Random-effect meta-analysis was used for exploring concentrations of inflammatory molecules in HD. Subgroup and sensitivity analyses were used to assess heterogeneity among the included studies. The study protocol has been registered in PROSPERO with the ID number CRD42022296078.
Ten studies were included in the meta-analysis. Plasma levels of Interleukin 6 (IL-6) and IL-10 were higher in HD compared to controls. Other biomarkers, namely, complement component C-reactive protein (CRP), C3, interferon-γ (IFN-γ), IL-1, IL-2, IL-8, and tumor necrosis factor-α (TNF-α), did not show any significant differences between the two groups. In addition, the subgroup analysis results established no significant differences in levels of these biomarkers in body fluids among premanifest and manifest HD patients.
The results of this study provide evidence for the presence of higher plasma levels of IL-6 and IL-10 in HD patients in comparison with healthy controls.
方法:在MEDLINE中进行了搜索,Scopus,WebofScience,和Embase数据库直到3月30日,2023年。随机效应荟萃分析用于探索HD中炎性分子的浓度。亚组和敏感性分析用于评估纳入研究之间的异质性。该研究方案已在PROSPERO中注册,ID号为CRD42022296078。
结果:10项研究纳入荟萃分析。与对照组相比,HD中的白细胞介素6(IL-6)和IL-10的血浆水平更高。其他生物标志物,即,补体成分C反应蛋白(CRP),C3,干扰素-γ(IFN-γ),IL-1,IL-2,IL-8和肿瘤坏死因子-α(TNF-α),两组之间没有显着差异。此外,亚组分析结果确定,在显证前和显证前的HD患者中,体液中这些生物标志物水平无显著差异.
结论:本研究的结果为HD患者与健康对照组相比存在更高的血浆IL-6和IL-10水平提供了证据。